Active	Status	Sponsor type	Region	Phase	Filter
1 Active 1 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
betifisolimab (MSB2311) / Transcenta
MSB2311-CSP-002 , NCT04272944: A Study of MSB2311 in Advanced Solid Tumors	Completed	1	42	RoW	10 mg/kg Q2W, MSB2311 10 Q2W, 20 mg/kg Q3W, MSB2311 20 Q3W	Suzhou Transcenta Therapeutics Co., Ltd.	Advanced Solid Tumor	01/22	01/22